US lawmakers blast patent thickets in letter to USPTO director
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US lawmakers blast patent thickets in letter to USPTO director

retro banner with red vintage typewriter with a blank sheet of p

Three Republican and two Democratic Congress members have claimed that patent thickets hinder access to affordable medicine

Members from both sides of the US House of Representatives wrote to USPTO director Kathi Vidal on Friday, March 24, expressing their concern about “patent thicketing.”

Five members – three Republicans and two Democrats – urged Vidal to consider implementing the proposed policies outlined in her October 4 2022 request for comment.

Vidal’s suggested that parties seeking to overcome rejections based on obvious variations of prior claims should stipulate that those claims aren’t patentably distinct.

Such admission would ensure that if one of the duplicates was invalidated, courts could consider that fact as evidence against the others, the members claimed.

“Branded manufacturers will often seek numerous patents on a single feature of a drug, creating a dense web, or thicket, of patents that delay generic and biosimilar competition,” the letter said.

“While some may question the quality of these patents, the high cost, uncertainty, and lengthy process for challenging them, makes it practically impossible to sort the good from the bad.”

The letter added that patent thickets, the process of seeking multiple patents on a single feature of drug, protected older drugs from competition, which costs the US government and taxpayers more money and hinders patients’ options for cost-effective treatment.

The signees were Republican Jodey Arrington, Michael Burgess and Darrell Issa, and Democrats Lloyd Doggett and Annie Kuster.

Vidal’s October 2022 request for comment came about after President Joe Biden issued an executive order to promote access to drugs in 2021 and after six senators raised concerns about patent thickets in a June 2022 letter to the USPTO.

more from across site and ros bottom lb

More from across our site

An intimate understanding of a client’s sector is essential to winning new business, a survey of over 28,000 corporate counsel reveals
Counsel say a Federal Circuit ruling on the obviousness test for design patents may increase the time IP owners spend defending their rights
While the INTA Annual Meeting is over for another year, here are a few things Managing IP learned after attending IP’s biggest party
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Four sources reveal which tools they have been using – or building – to help them with a range of tasks from invention generation to claim sufficiency
Managing IP reveals Wednesday's highlights, including a discussion on how AI is helping lawyers improve their "gut instinct" trademark decisions
Managing IP reveals Tuesday’s highlights, including an illuminating discussion celebrating women in the workplace and the challenges that remain
Dana Northcott, INTA’s 2024 president and associate general counsel for Amazon's IP team, talks about her work for the association
Managing IP reveals highlights from the INTA Annual Meeting, including law firms’ diversity and ESG concerns and a new beginning for a Chinese firm
Firms with a broad geographic reach are more likely to win work, especially from global companies with high turnovers, according to survey data of nearly 29,000 corporate counsel
Gift this article